Thalidomide-O-PEG3-Propargyl CAS:2098799-76-7 is a type of small molecule drug that is used in the treatment of certain types of cancer and inflammatory diseases. It is composed of several functional groups, including a thalidomide group, a polyethylene glycol (PEG) spacer, and a propargyl group.
Thalidomide is a type of immunomodulatory drug that has been shown to be effective in treating certain types of cancer, such as multiple myeloma and myelodysplastic syndromes, as well as inflammatory diseases such as rheumatoid arthritis and Crohn’s disease. The PEG spacer in Thalidomide-O-PEG3-Propargyl is used to improve the solubility and stability of the drug in solution, allowing it to be more easily administered to patients. The propargyl group is important for the chemical reactivity of the compound.
In terms of its mechanism of action, Thalidomide-O-PEG3-Propargyl works by modulating the activity of certain immune cells in the body, particularly T cells and natural killer cells. By enhancing the activity of these cells, Thalidomide-O-PEG3-Propargyl can help to boost the body’s immune response to cancer cells and reduce inflammation, leading to improved outcomes for patients with cancer and inflammatory diseases.
The propargyl group in Thalidomide-O-PEG3-Propargyl is also important for its potential use in bioconjugation, a technique used to attach molecules such as antibodies or imaging agents to drugs. The propargyl group can be used to attach Thalidomide-O-PEG3-Propargyl to other molecules, allowing for targeted delivery of the drug to specific cells or tissues.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
